Prospective Grant of Exclusive License: Development of Cripto-1 Point of Care (POC) Tests and Kits for the Detection of Colon and Rectal Cancer, Breast Cancer, and Lung Cancer, 73553 [2013-29099]
Download as PDF
<![CDATA[
Federal Register / Vol. 78, No. 235 / Friday, December 6, 2013 / Notices
Dated: December 2, 2013.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2013–29097 Filed 12–5–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: Development of Cripto-1
Point of Care (POC) Tests and Kits for
the Detection of Colon and Rectal
Cancer, Breast Cancer, and Lung
Cancer
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
This is notice, in accordance
with 35 U.S.C. 209 and 37 CFR Part 404,
that the National Institutes of Health,
Department of Health and Human
Services, is contemplating the grant of
an exclusive patent license to practice
the inventions embodied in the
following U.S. Patents and Patent
Applications to Beacon Biomedical LLC
(‘‘Beacon’’) located in Scottsdale, AZ,
USA.
SUMMARY:
emcdonald on DSK67QTVN1PROD with NOTICES
Intellectual Property: U.S. Patent
No.7,078,176 issued July 18, 2006 entitled
‘‘Detection and Quantification of Cripto-1’’
[HHS Ref. No. E–290–2000/0–US–03] and
foreign equivalents thereof.
The patent rights in these inventions
have been assigned to the government of
the United States of America.
The prospective exclusive license
territory may be worldwide and the
field of use will be limited to the use of
Licensed Patent Rights to develop FDA
approved and/or 510K cleared Point of
Care (POC) tests and kits for the purpose
of disease state recognition, detection,
diagnosis, monitoring, association and
risk-stratification of colon and rectal
cancer, breast cancer, and lung cancer.
DATES: Only written comments and/or
applications for a license which are
received by the NIH Office of
Technology Transfer on or before
January 6, 2014 will be considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
exclusive license should be directed to:
Eggerton Campbell, Ph.D. Licensing and
Patenting Manager, Cancer Branch,
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville, MD
20852–3804; Telephone: (301) 435–
VerDate Mar<15>2010
17:28 Dec 05, 2013
Jkt 232001
5282; Facsimile: (301) 435–4013; Email:
Eggerton.Campbell@.nih.gov.
DEPARTMENT OF HOMELAND
SECURITY
Cripto-1
(CR1) is a member of the epidermal
growth factor (EGF)-related families of
peptides and is involved in the
development and progression of various
human carcinomas. In particular, CR1
overexpression has been detected in 50–
90% of carcinomas of the colon,
pancreas, stomach, gallbladder, breast,
lung, endometrium and cervix. Current
methodologies of cancer detection, e.g.
immunohistochemistry, can be time
consuming, inconvenient and
oftentimes, inaccurate, and therefore, a
need exists for more efficient, reliable
and less time consuming methods of
detection. The invention relates to such
a method of detection. This test could
be used to more effectively screen and
perhaps stage cancers. Additionally,
should particular tumor cells, e.g. breast
tumor cells, express a sufficiently high
level of CR1, it may be possible to use
the disclosed assay to detect and
measure CR1 in human serum and/or
plasma and possibly other physiological
fluids.
The prospective exclusive license will
be royalty bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR Part 404.7. The
prospective exclusive license may be
granted unless within thirty (30) days
from the date of this published notice,
the NIH receives written evidence and
argument that establishes that the grant
of the license would not be consistent
with the requirements of 35 U.S.C. 209
and 37 CFR 404.7.
Applications for a license in the field
of use filed in response to this notice
will be treated as objections to the grant
of the contemplated exclusive license.
Comments and objections submitted to
this notice will not be made available
for public inspection and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
73553
United States Immigration and
Customs Enforcement
SUPPLEMENTARY INFORMATION:
Dated: December 2, 2013.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2013–29099 Filed 12–5–13; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
Agency Information Collection
Activities: Comment Request
30-Day Notice of Information
Collection for Review; Form No. I–246,
Application for Stay of Removal or
Deportation; OMB Control No. 1653–
0021.
ACTION:
The Department of Homeland
Security, U.S. Immigration and Customs
Enforcement (USICE), will submit the
following information collection request
for review and clearance in accordance
with the Paperwork Reduction Act of
1995. The information collection is
published in the Federal Register to
obtain comments from the public and
affected agencies. The information
collection was previously published in
the Federal Register on September 16,
2013, Vol. 78 No. 23447 allowing for a
60 day comment period. USICE received
no comments during this period. The
purpose of this notice is to allow an
additional 30 days for public comments.
Written comments and suggestions
regarding items contained in this notice
and especially with regard to the
estimated public burden and associated
response time should be directed to the
Office of Information and Regulatory
Affairs, Office of Management and
Budget. Comments should be addressed
to the OMB Desk Officer for U.S.
Immigration and Customs Enforcement,
Department of Homeland Security, and
sent via electronic mail to oira_
submission@omb.eop.gov or faxed to
(202) 395–5806.
Written comments and suggestions
from the public and affected agencies
concerning the proposed collection of
information should address one or more
of the following four points:
(1) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
(2) Evaluate the accuracy of the
agencies estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
(3) Enhance the quality, utility, and
clarity of the information to be
collected; and
(4) Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
E:\FR\FM\06DEN1.SGM
06DEN1
]]>Agencies
[Federal Register Volume 78, Number 235 (Friday, December 6, 2013)]
[Notices]
[Page 73553]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-29099]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: Development of Cripto-1
Point of Care (POC) Tests and Kits for the Detection of Colon and
Rectal Cancer, Breast Cancer, and Lung Cancer
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209 and 37 CFR
Part 404, that the National Institutes of Health, Department of Health
and Human Services, is contemplating the grant of an exclusive patent
license to practice the inventions embodied in the following U.S.
Patents and Patent Applications to Beacon Biomedical LLC (``Beacon'')
located in Scottsdale, AZ, USA.
Intellectual Property: U.S. Patent No.7,078,176 issued July 18,
2006 entitled ``Detection and Quantification of Cripto-1'' [HHS Ref.
No. E-290-2000/0-US-03] and foreign equivalents thereof.
The patent rights in these inventions have been assigned to the
government of the United States of America.
The prospective exclusive license territory may be worldwide and
the field of use will be limited to the use of Licensed Patent Rights
to develop FDA approved and/or 510K cleared Point of Care (POC) tests
and kits for the purpose of disease state recognition, detection,
diagnosis, monitoring, association and risk-stratification of colon and
rectal cancer, breast cancer, and lung cancer.
DATES: Only written comments and/or applications for a license which
are received by the NIH Office of Technology Transfer on or before
January 6, 2014 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
and comments relating to the contemplated exclusive license should be
directed to: Eggerton Campbell, Ph.D. Licensing and Patenting Manager,
Cancer Branch, Office of Technology Transfer, National Institutes of
Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804;
Telephone: (301) 435-5282; Facsimile: (301) 435-4013; Email:
Eggerton.Campbell@.nih.gov.
SUPPLEMENTARY INFORMATION: Cripto-1 (CR1) is a member of the epidermal
growth factor (EGF)-related families of peptides and is involved in the
development and progression of various human carcinomas. In particular,
CR1 overexpression has been detected in 50-90% of carcinomas of the
colon, pancreas, stomach, gallbladder, breast, lung, endometrium and
cervix. Current methodologies of cancer detection, e.g.
immunohistochemistry, can be time consuming, inconvenient and
oftentimes, inaccurate, and therefore, a need exists for more
efficient, reliable and less time consuming methods of detection. The
invention relates to such a method of detection. This test could be
used to more effectively screen and perhaps stage cancers.
Additionally, should particular tumor cells, e.g. breast tumor cells,
express a sufficiently high level of CR1, it may be possible to use the
disclosed assay to detect and measure CR1 in human serum and/or plasma
and possibly other physiological fluids.
The prospective exclusive license will be royalty bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR Part
404.7. The prospective exclusive license may be granted unless within
thirty (30) days from the date of this published notice, the NIH
receives written evidence and argument that establishes that the grant
of the license would not be consistent with the requirements of 35
U.S.C. 209 and 37 CFR 404.7.
Applications for a license in the field of use filed in response to
this notice will be treated as objections to the grant of the
contemplated exclusive license. Comments and objections submitted to
this notice will not be made available for public inspection and, to
the extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: December 2, 2013.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2013-29099 Filed 12-5-13; 8:45 am]
BILLING CODE 4140-01-P
